• Global sales (excl China) up 32% to US$4.9 million
• Last 12 months revenue surpasses A$30 million
• Group cash outflow from operations continues to improve

Nova Eye Medical Limited, a medical technology company focused on advanced ophthalmic treatment technologies and devices, has reported its quarterly activities and Appendix 4C cash flow report for the three months ended 30 September 2025. The company achieved strong sales growth in Q1FY26, with global sales excluding China up 32% to US$4.9 million (A$7.5 million). The company's last 12 months revenue surpassed A$30 million (US$19.8 million), with 87% of this revenue generated by the company's own sales team in Germany and the USA. The group's cash outflow from operations continued to improve quarter-on-quarter, with A$798,000 reported for Q1FY26. The company also announced that the National Medical Products Administration (NMPA) in China has registered the iTrack™ Advance, a pivotal milestone in the company's strategy to expand global sales of its iTrack™ portfolio for the surgical treatment of glaucoma. For the financial year ending 30 June 2026, the company provided guidance of sales revenue (excluding China) expected to range between US$21 million and US$24 million (A$32 million to A$37 million), and expects to achieve EBITDA breakeven in H2FY26.

FY26 sales revenue (excluding China) expected to range between US$21 million and US$24 million (A$32 million to A$37 million). The group is currently expected to achieve breakeven EBITDA in H2FY26.

The company continues to monitor trade negotiations between the USA and China, as the size and nature of any tariffs imposed by China on USA products may impact the company's sales. The company is also working with potential partners on leveraging its iTrack™ technology for targeted drug delivery within the eye.